DE69940980D1 - Rana pipiens proteine und deren verwendung in der behandlung von tumoren - Google Patents

Rana pipiens proteine und deren verwendung in der behandlung von tumoren

Info

Publication number
DE69940980D1
DE69940980D1 DE69940980T DE69940980T DE69940980D1 DE 69940980 D1 DE69940980 D1 DE 69940980D1 DE 69940980 T DE69940980 T DE 69940980T DE 69940980 T DE69940980 T DE 69940980T DE 69940980 D1 DE69940980 D1 DE 69940980D1
Authority
DE
Germany
Prior art keywords
proteins
tumors
treatment
rana pipiens
rana
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940980T
Other languages
English (en)
Inventor
Wojciech Ardelt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tamir Biotechnology Inc
Original Assignee
Alfacell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfacell Corp filed Critical Alfacell Corp
Application granted granted Critical
Publication of DE69940980D1 publication Critical patent/DE69940980D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69940980T 1998-12-30 1999-12-24 Rana pipiens proteine und deren verwendung in der behandlung von tumoren Expired - Lifetime DE69940980D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/223,118 US6239257B1 (en) 1998-12-30 1998-12-30 Family of proteins belonging to the pancreatic ribonuclease a superfamily
PCT/US1999/030799 WO2000040608A1 (en) 1998-12-30 1999-12-24 Proteins from rana pipiens and their use in the treatment of tumors

Publications (1)

Publication Number Publication Date
DE69940980D1 true DE69940980D1 (de) 2009-07-23

Family

ID=22835123

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940980T Expired - Lifetime DE69940980D1 (de) 1998-12-30 1999-12-24 Rana pipiens proteine und deren verwendung in der behandlung von tumoren

Country Status (6)

Country Link
US (1) US6239257B1 (de)
EP (1) EP1141004B1 (de)
JP (1) JP4516216B2 (de)
AT (1) ATE433461T1 (de)
DE (1) DE69940980D1 (de)
WO (1) WO2000040608A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229824B2 (en) * 2003-07-17 2007-06-12 Alfacell Corporation Ribonucleases and methods of making them recombinantly
JP2008546391A (ja) 2005-06-16 2008-12-25 ウイスコンシン アラムニ リサーチ ファンデーション 細胞傷害性リボヌクレアーゼ変異株
JP5114392B2 (ja) 2005-06-16 2013-01-09 ウイスコンシン アラムニ リサーチ ファンデーション 細胞傷害性リボヌクレアーゼ変異株
CN100372869C (zh) * 2006-04-18 2008-03-05 河北师范大学 棕点湍蛙抗微生物多肽及其在制药中的应用
DK2496691T3 (en) 2009-11-02 2017-06-06 Univ Washington THERAPEUTIC NUCLEASE COMPOSITIONS AND PROCEDURES
EP3449933A1 (de) 2011-04-29 2019-03-06 University of Washington Therapeutische nukleasezusammensetzungen und verfahren dafür
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
WO2015148768A2 (en) 2014-03-28 2015-10-01 Tamir Biotechnology, Inc. Rnase for use in treating or preventing viral infections
US9919034B2 (en) 2014-03-28 2018-03-20 Tamir Biotechnology, Inc. Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V
US10835598B2 (en) 2014-08-18 2020-11-17 Orgenesis Inc. Prophylactic protection against viral infections, particularly HIV
US9642794B2 (en) 2014-08-18 2017-05-09 Tamir Biotechnology, Inc. Antiviral pharmaceutical for topical administration
US10293032B2 (en) 2015-06-15 2019-05-21 Tamir Biotechnology, Inc. Methods and pharmaceuticals for treatment of viral infections of the eye
WO2017053923A1 (en) 2015-09-25 2017-03-30 Okogen, Llc Viral conjunctivitis treatment using ranpirnase and/or amphinase
WO2017142807A1 (en) 2016-02-16 2017-08-24 Tamir Biotechnology, Inc. Treatment or prevention of zika virus infections by administration of a ribonuclease
HRP20240603T1 (hr) 2016-07-01 2024-07-19 Resolve Therapeutics, Llc Optimizirane fuzije binukleaze i postupci njihove upotrebe
WO2018022774A1 (en) 2016-07-26 2018-02-01 Squiquera Luis Prophylactic protection against viral infections
US11331378B2 (en) 2016-07-26 2022-05-17 Orgenesis Inc. Prophylactic protection against viral infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882421A (en) * 1982-09-23 1989-11-21 Alfacell Corporation Pharmaceutical for treating tumors and method for making it
US5559212A (en) * 1988-04-06 1996-09-24 Alfacell Corporation Frog embryo and egg-derived tumor cell anti-proliferation protein
US5728805A (en) * 1988-04-06 1998-03-17 Alfacell Corp. Pharmaceuticals and method for making them
JP2972334B2 (ja) * 1989-11-13 1999-11-08 アルフアセル・コーポレイシヨン 精製された蛋白質および生物活性治療薬
NZ331298A (en) * 1996-02-21 2000-03-27 Us Gov Health & Human Serv Recombinant (humanised) ribonuclease proteins derived from a native ribonuclease found in the oocytes of Rana pipiens and uses therefor

Also Published As

Publication number Publication date
JP4516216B2 (ja) 2010-08-04
US6239257B1 (en) 2001-05-29
EP1141004A1 (de) 2001-10-10
JP2002534075A (ja) 2002-10-15
WO2000040608A1 (en) 2000-07-13
EP1141004B1 (de) 2009-06-10
ATE433461T1 (de) 2009-06-15

Similar Documents

Publication Publication Date Title
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ES2155817T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
DE69939864D1 (de) Ppar-gamma modulatoren
ATE349428T1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ES2154253T1 (es) Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas.
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
ATE222769T1 (de) Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
DE69738045D1 (de) Verwendung von cetrorelix zur behandlung von benigne prostatahypertrophie und prostatakrebs
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE257152T1 (de) N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
PT782630E (pt) Gene da doenca poliquistica do rim
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
CO4920227A1 (es) Histidina-n-bencil glicinamida sustituida con cicloalquilos .
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
8364 No opposition during term of opposition